Effects of 225Ac-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis

Abstract

Prostate-specific membrane antigen (PSMA), overexpressed in pros tate cancer, has become a popular target for radionuclide-based theranostic applications in the advanced stages of prostate cancer. We conducted a meta-analysis of the therapeutic effects of PSMA-tar geting a-therapy (225Ac-PSMA radioligand therapy [RLT]) in patients with metastatic castration-resistant prostate cancer (mCRPC). Methods: A systematic search was performed using the keywords “mCRPC,” “225Ac-PSMA,” and “alpha therapy.” Therapeutic responses were analyzed as the pooled proportions of patients with more than a 50% prostate-specific antigen (PSA) decline and any PSA decline. Survival outcomes were analyzed by estimating summary survival curves for progression-free survival and overall survival. Adverse events were analyzed as the pooled proportions of patients with xerostomia and severe hematotoxicity (anemia, leukocytopenia, and thrombocytope nia). Results: Nine studies with 263 patients were included in our meta-analysis. The pooled proportions of patients with more than a 50% PSA decline and any PSA decline were 60.99% (95% CI, 54.92%–66.83%) and 83.57% (95% CI, 78.62%–87.77%), respec tively. The estimated mean progression-free survival and mean overall survival were 9.15 mo (95% CI, 6.69–11.03 mo) and 11.77 mo (95% CI, 9.51–13.49 mo), respectively. The pooled proportions of patients with adverse events were 62.81% (95% CI, 39.34%–83.46%) for xerostomia, 14.39% (95% CI, 7.76%–22.63%) for anemia, 4.12% (95% CI, 0.97%–9.31%) for leukocytopenia, and 7.18% (95% CI, 2.70%–13.57%) for thrombocytopenia. Conclusion: In our study, around 61% of patients had more than a 50% PSA decline and 84% of patients had any PSA decline after 225Ac-PSMA RLT. The common adverse events in 225Ac-PSMA RLT were xerostomia in 63% of patients and severe hematotoxicity in 4%–14% of patients.